EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia

Phase 2

Completed

Conditions: Idiopathic Hypersomnia
Narcolepsy Without Cataplexy

Interventions: Drug: Modafinil
Drug: Amphetamine-Dextroamphetamine

First Posted Date: 2018-12-11

Last Posted Date: 2024-05-23

Lead Sponsor: Emory University

Target Recruit Count: 44

Registration Number: NCT03772314

Locations: 🇺🇸
Emory Sleep Center, Atlanta, Georgia, United States

VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

Phase 1

Active, not recruiting

Conditions: Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8

Interventions: Biological: Ipilimumab
Biological: VX15/2503
Biological: Nivolumab
Procedure: Surgery

First Posted Date: 2018-12-07

Last Posted Date: 2024-02-26

Lead Sponsor: Emory University

Target Recruit Count: 41

Registration Number: NCT03769155

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

A Rigorous Evaluation of the Relationship Between Physical Activity and Education Outcomes

Not Applicable

Completed

Conditions: Physical Activity

Interventions: Behavioral: Intervention Arm

First Posted Date: 2018-12-05

Last Posted Date: 2020-07-14

Lead Sponsor: Emory University

Target Recruit Count: 4968

Registration Number: NCT03765047

Locations: 🇺🇸
Gwinnett County Elementary Schools, Lawrenceville, Georgia, United States

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

Phase 2

Active, not recruiting

Conditions: Prostate Adenocarcinoma

Interventions: Procedure: Computed Tomography
Drug: Fluciclovine F18
Radiation: Gallium Ga68-labeled PSMA-11
Procedure: Positron Emission Tomography

First Posted Date: 2018-12-04

Last Posted Date: 2024-05-17

Lead Sponsor: Emory University

Target Recruit Count: 140

Registration Number: NCT03762759

Locations: 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

HealthMindr App to Increase Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex With Men (MSM)

Not Applicable

Completed

Conditions: HIV Infections

Interventions: Behavioral: HealthMindr App
Behavioral: Control App

First Posted Date: 2018-12-04

Last Posted Date: 2024-06-04

Lead Sponsor: Emory University

Target Recruit Count: 658

Registration Number: NCT03763942

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
George Washington University, Washington, District of Columbia, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone
Drug: Pomalidomide

First Posted Date: 2018-11-28

Last Posted Date: 2024-03-08

Lead Sponsor: Emory University

Target Recruit Count: 29

Registration Number: NCT03756896

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients

Phase 4

Terminated

Conditions: Stress Hyperglycemia

Interventions: Drug: Dulaglutide Injection
Other: Saline Injection

First Posted Date: 2018-11-15

Last Posted Date: 2024-05-30

Lead Sponsor: Emory University

Target Recruit Count: 28

Registration Number: NCT03743025

Locations: 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Emory Hospital Midtown, Atlanta, Georgia, United States

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Recurrent Hodgkin Lymphoma
Classical Hodgkin Lymphoma
Hodgkin Lymphoma
Refractory Hodgkin Lymphoma

Interventions: Drug: Bendamustine
Drug: Gemcitabine
Biological: Nivolumab

First Posted Date: 2018-11-14

Last Posted Date: 2024-03-04

Lead Sponsor: Emory University

Target Recruit Count: 54

Registration Number: NCT03739619

Locations: 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

IDegLira HIGH Trial

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: IDegLira
Drug: Insulin Degludec (U-100)
Drug: Insulin Aspart

First Posted Date: 2018-11-09

Last Posted Date: 2023-09-08

Lead Sponsor: Emory University

Target Recruit Count: 145

Registration Number: NCT03737240

Locations: 🇺🇸
Emory Clinic, Atlanta, Georgia, United States
🇺🇸
Grady Health System, Atlanta, Georgia, United States

Electronic Pre-exposure Prophylaxis (PrEP) Initiation and Maintenance Home Care System

Not Applicable

Completed

Conditions: Pre-exposure Prophylaxis

Interventions: Other: ePrEP

First Posted Date: 2018-11-02

Last Posted Date: 2024-10-18

Lead Sponsor: Emory University

Target Recruit Count: 217

Registration Number: NCT03729570

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Rollins School of Public Health, Atlanta, Georgia, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy